SCHEMBL2128582

SCHEMBL2128582

N=C(N)c1ccc2nc(-c3ccc(F)cc3)cn2c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 5/20 0.57
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
APP P05067 1/20 0.51
CLK1 P49759 1/20 0.50
DYRK1A Q13627 1/20 0.50
ALDH1A1 P00352 8/20 0.49
KDM4E B2RXH2 6/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
POLB P06746 3/20 0.49
GAA P10253 2/20 0.49
HPGDS O60760 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MITF O75030 1/20 0.46
KDM5A P29375 1/20 0.46
KDM5C P41229 1/20 0.46
PAX8 Q06710 1/20 0.46
HSP90AA1 P07900 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2128057 0.90 ALDH1A3 (0.51) ALDH1A3NPC1RAB9AAPPCLK1
SCHEMBL4951218 0.90 ALDH1A1 (0.53) ALDH1A3NPC1RAB9AAPPALDH1A1
SCHEMBL1691332 0.86 DYRK1A (0.60) ALDH1A3NPC1RAB9AAPPCLK1
SCHEMBL8867016 0.84 ALDH1A1 (0.61) ALDH1A3NPC1RAB9AAPPCLK1
SCHEMBL2126828 0.83 ALDH1A3 (0.55) ALDH1A3NPC1RAB9AAPPCLK1
SCHEMBL2126832 0.83 ALDH1A3 (0.55) ALDH1A3NPC1RAB9AAPPCLK1
Acetic Acid SCHEMBL4952379 0.82 ALDH1A1 (0.55) ALDH1A3NPC1RAB9AALDH1A1KDM4E
SCHEMBL2127192 0.81 ALDH1A1 (0.67) ALDH1A3NPC1RAB9AAPPCLK1
SCHEMBL22906630 0.80 APP (0.73) ALDH1A3NPC1RAB9AAPPCLK1
SCHEMBL4954128 0.80 NR4A2 (0.54) ALDH1A3NPC1RAB9ACLK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US claimed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP claimed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US claimed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP claimed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO claimed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP claimed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 ALDH1A3 2825/4885NPC1 2959/4885RAB9A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.